# Avenue Biosciences

> Avenue Biosciences is a transatlantic biotech building the first platform to measure and modulate the cellular secretory pathway at scale. Spun out of the University of Helsinki and headquartered between Helsinki and Palo Alto, the company pairs high-throughput chemistry with machine learning to design signal peptides and boost yields of therapeutic proteins - biologics, biosimilars, and mRNA-encoded medicines - so that production bottlenecks stop limiting which therapies reach patients.

- **Founded:** 2023
- **Headquarters:** Palo Alto, United States (with R&D in Helsinki, Finland)
- **Founders:** Tero-Pekka Alastalo (CEO & Co-founder), Ville Paavilainen (Co-founder & Research Director (University of Helsinki)), Katja Rosti (COO & Co-founder), Juho Kellosalo (CSO & Co-founder)
- **Team size:** ~21 employees
- **Products:** Signal Peptide Platform, Secretory Pathway Modulation, Protein Engineering Services
- **Notable:** Closed $8.2M in total seed-stage funding by January 2026, Built the first scalable platform for measuring secretory pathway efficiency across thousands of variants, Selected for BIO International Convention 2026

## Products & services

- **Signal Peptide Platform** — A high-throughput screening and ML-driven design system that evaluates thousands of natural and synthetic signal peptides in parallel to identify the best one for a given protein of interest.
- **Secretory Pathway Modulation** — Proprietary chemistry and biology tools that tune how host cells fold, modify, and secrete recombinant proteins - boosting yield and quality for monoclonal antibodies, biosimilars, and engineered proteins.
- **Protein Engineering Services** — Partnered campaigns with biopharma and biotech customers to optimize expression of difficult-to-produce proteins.

## Achievements

- Closed $8.2M in total seed-stage funding by January 2026
- Built the first scalable platform for measuring secretory pathway efficiency across thousands of variants
- Selected for BIO International Convention 2026
- Spinout from the Paavilainen Lab at the University of Helsinki

## Latest updates

- **2026-01** — Raised $5.7M seed extension co-led by Balnord and Tesi, bringing total funding to $8.2M.
- **2024-10** — Closed $2.5M seed led by Voima Ventures.
- **2026** — Selected for the BIO International Convention startup program.

## Links

- Website: https://avenuebiosciences.com
- LinkedIn: https://www.linkedin.com/company/avenue-biosciences
- Instagram: https://www.instagram.com/avenuebiosciences/

---

Profile page: https://yespress.io/avenue-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-29